



1. PATIENT INFORMATION

Patient Name	<input type="checkbox"/> Male <input type="checkbox"/> Female	Allergies	<input type="checkbox"/> NKDA
Date of Birth	SSN#	Weight _____ kg/ lb	Height _____ cm/ in
Address	City	State	Zip
Phone # (Home)	(Work)	Email address(optional)	

2. INSURANCE INFORMATION (PLEASE FAX A COPY OF FRONT AND BACK OF THE INSURANCE CARD(S)).

Primary Insurance	RX Ins: BIN _____ PCN _____	Policyholder:
Group #	Policy #	Phone #
Secondary Insurance	Policy #	Phone #
Local Pharmacy:	Pharmacy Phone:	

3. DIAGNOSIS/MEDICAL INFORMATION (PLEASE ANSWER ALL QUESTIONS TO PREVENT A DELAY IN PATIENT'S THERAPY.)

<input type="checkbox"/> M06.9 (Rheumatoid Arthritis)	<input type="checkbox"/> M08.0 (Juvenile Idiopathic Arthritis)	<input type="checkbox"/> L40.59 (Psoriatic Arthritis)
<input type="checkbox"/> L40.54 (Psoriatic Juvenile Arthritis)	<input type="checkbox"/> _____	Diagnosis Date: _____ TB test: <input type="checkbox"/> Yes <input type="checkbox"/> No Negative Test Date: _____
Prior Therapy: <input type="checkbox"/> Yes <input type="checkbox"/> No	Reason for Discontinuation of Therapy:	Approximate Start Date: _____ Approximate End Date: _____

Comorbidities: _____
Concomitant Medications: _____

4. PRESCRIPTION INFORMATION

Actemra[®], Cimzia[®], and Enbrel[®] are available on the Rheumatoid Arthritis Form A-E
Humira[®], Orencia[®], and Otezla[®] are available on the Rheumatoid Arthritis Form F-R

<input type="checkbox"/> Simponi [®] (golimumab)	<input type="checkbox"/> Inject 50 mg subcut once a month	<input type="checkbox"/> 1 x 50mg/0.5mL	<input type="checkbox"/> PFS <input type="checkbox"/> SmartJect [®] Autoinjector	_____
<input type="checkbox"/> Stelara [®] (ustekinumab)	<input type="checkbox"/> Inject 45mg subcut on Day 1 (≤100kg) <input type="checkbox"/> Inject 90mg subcut on Day 1 (>100kg)	<input type="checkbox"/> 1 x 45mg/0.5mL <input type="checkbox"/> 1 x 90 mg/mL	PFS	_____
	<input type="checkbox"/> Inject 45mg subcut on Day 29 and every 12 weeks thereafter (≤100kg) <input type="checkbox"/> Inject 90mg subcut on Day 29 and every 12 weeks thereafter (>100kg)	<input type="checkbox"/> 1 x 45 mg/0.5mL <input type="checkbox"/> 1 x 90 mg/mL	PFS	_____
<input type="checkbox"/> Taltz [®] (ixekizumab)	<input type="checkbox"/> 160 mg (2 pens) Week 0, 80 mg (1 pen) weeks 2,4,6,8,10 and 12, then 80 mg (1 pen) every 4 weeks	80 mg/pen	<input type="checkbox"/> 4 pens (starter)	_____
	<input type="checkbox"/> Maintenance dose: 1 pen every 4 weeks		<input type="checkbox"/> 1 pen every 4 weeks	_____
<input type="checkbox"/> Xeljanz [®] (tofacitinib)	<input type="checkbox"/> Take 5mg by mouth twice daily	<input type="checkbox"/> 60 x 5 mg tablets <input type="checkbox"/> _____		_____
<input type="checkbox"/> Xeljanz [®] XR (tofacitinib)	<input type="checkbox"/> Take 11mg by mouth twice daily	<input type="checkbox"/> 30 x 11mg tablets		_____

Injection Training Provided by: Prescriber's Office Pharmacy Other: _____

Per state-specific law, prescriptions will be dispensed as generic, if applicable, unless notated otherwise: _____

5. DELIVERY INSTRUCTIONS

<input type="checkbox"/> Physician's Office	<input type="checkbox"/> Other	Date Medication Needed:
<input type="checkbox"/> Patient's Home	Address	
	City/State/Zip	If shipping to prescriber: <input type="checkbox"/> First Fill <input type="checkbox"/> Always <input type="checkbox"/> Never

6. PHYSICIAN CONTACT INFORMATION & AUTHORIZATION

Physician Name	Office Contact	
Phone	Fax	Specialty
Address	City/State/Zip	

License #	DEA #
Physician's Signature _____ Date _____ (required to process prescription – stamped signatures are not permissible) I authorize AllyScripts and its representatives to act as an agent to initiate and execute the insurance prior authorization process for this prescription and any future fills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice.	

AllyScripts 11/18

Please fax to AllyScripts Specialty Pharmacy at 844-309-7173.
Faxed prescription forms will only be accepted from prescribing practitioners.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is except from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the indented recipient) or copying the information. If you received this communication in error, please fax to AllyScripts Specialty Pharmacy at 844-309-7173.